UnknownPhase 3

Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis

France105 participantsStarted 2013-10

Plain-language summary

The purpose of this study is to demonstrate the superiority of MD1003 over placebo in the visual improvement of patients suffering from chronic visual loss resulting from multiple sclerosis related optic neuritis.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Diagnosis criteria of MS fulfilling revised Mc Donald criteria (2010)
✓. Uni-or bilateral optic neuropathy with worst eye VA≤ 5/10 confirmed at 6 months
✓. Worsening of visual acuity during the last three years
✓. Informed consent prior to any study procedure
✓. Patient aged 18-75 years

Exclusion criteria

✕. Optic neuritis relapse within the three months before inclusion
✕. Normal RNFL at OCT
✕. Presence of other ocular pathology (glaucoma, cataract, retinopathy, anterior uveitis, myopia\>7 dioptrics, intraocular pressure\>20 mm Hg, amblyopia, retinal or optic head abnormalities (drusen, tilted disc)
✕. Bilateral visual acuity \<1/20
✕. Visual impairment caused by ocular flutter or nystagmus
✕. Pregnancy or childbearing potential woman without contraception
✕. Any general chronic handicapping disease other than MS
✕. New treatment introduced less than 3 months prior to inclusion or less than 1 month for Fampridine

What they're measuring

Change from baseline of the best corrected visual acuity at 100% contrast

Timeframe: Baseline, 6 months

Trial details

NCT IDNCT02220244

SponsorMedDay Pharmaceuticals SA

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2015-12

View on ClinicalTrials.gov More Multiple Sclerosis trials